UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 30

Sortiert nach

A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects

Cell metabolism, 2016-03, Vol.23 (3), p.427-440

2016

Volltextzugriff (PDF)

Cellular Imaging Predictions of Clinical Drug-Induced Liver Injury

Toxicological sciences, 2008-09, Vol.105 (1), p.97-105

2008

Volltextzugriff (PDF)

Pharmacokinetics (PK), pharmacodynamics (PD) and integrated PK/PD modeling of a novel long acting FGF21 clinical candidate PF-05231023 in diet-induced obese and leptin-deficient obese mice

PloS one, 2015-03, Vol.10 (3), p.e0119104-e0119104

2015

Volltextzugriff (PDF)

Fc-GDF15 glyco-engineering and receptor binding affinity optimization for body weight regulation

Scientific reports, 2021-04, Vol.11 (1), p.8921-12, Article 8921

2021

Volltextzugriff (PDF)

Stochastic gene expression out-of-steady-state in the cyanobacterial circadian clock

Nature, 2007-12, Vol.450 (7173), p.1249-1252

2007

Volltextzugriff (PDF)

Examination of the Human Cytochrome P4503A4 Induction Potential of PF-06282999, an Irreversible Myeloperoxidase Inactivator: Integration of Preclinical, In Silico, and Biomarker Methodologies in the Prediction of the Clinical Outcome

Drug metabolism and disposition, 2017-05, Vol.45 (5), p.501-511

2017

Volltextzugriff (PDF)

Probing Polymerization Forces by Using Actin-Propelled Lipid Vesicles

Proceedings of the National Academy of Sciences - PNAS, 2003-04, Vol.100 (8), p.4521-4526

2003

Volltextzugriff (PDF)

Assessing the Feasibility of Neutralizing Osteopontin with Various Therapeutic Antibody Modalities

Scientific reports, 2018-05, Vol.8 (1), p.7781-7, Article 7781

2018

Volltextzugriff (PDF)

A Mechanistic Site-Of-Action Model: A Tool for Informing Right Target, Right Compound, And Right Dose for Therapeutic Antagonistic Antibody Programs

Frontiers in bioinformatics, 2021-09, Vol.1, p.731340-731340

2021

Volltextzugriff (PDF)

Once‐weekly administration of a long‐acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with hypertriglyceridaemia and in non‐human primates

Diabetes, obesity & metabolism, 2017-12, Vol.19 (12), p.1762-1772

2017

Volltextzugriff (PDF)

Social context of shell acquisition in Coenobita clypeatus hermit crabs

Behavioral ecology, 2010-05, Vol.21 (3), p.639-646

2010

Volltextzugriff (PDF)

Small Molecule Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Hit to Lead Optimization of Systemic Agents

Journal of medicinal chemistry, 2018-07, Vol.61 (13), p.5704-5718

2018

Volltextzugriff (PDF)

Liver‐Targeted Small‐Molecule Inhibitors of Proprotein Convertase Subtilisin/Kexin Type 9 Synthesis

Angewandte Chemie International Edition, 2017-12, Vol.56 (51), p.16218-16222

International ed. in English, 2017

Volltextzugriff (PDF)

Physiologically relevant binding affinity quantification of monoclonal antibody PF‐00547659 to mucosal addressin cell adhesion molecule for in vitro in vivo correlation

British journal of pharmacology, 2017-01, Vol.174 (1), p.70-81

2017

Volltextzugriff (PDF)

Glyco-engineered Long Acting FGF21 Variant with Optimal Pharmaceutical and Pharmacokinetic Properties to Enable Weekly to Twice Monthly Subcutaneous Dosing

Scientific reports, 2018-03, Vol.8 (1), p.4241-15, Article 4241

2018

Volltextzugriff (PDF)

Analysis of Mechanistic Pathway Models in Drug Discovery: p38 Pathway

Biotechnology progress, 2008-01, Vol.24 (1), p.96-109

2008

Volltextzugriff (PDF)

Two additive mechanisms impair the differentiation of 'substrate-selective' p38 inhibitors from classical p38 inhibitors in vitro

BMC systems biology, 2010-03, Vol.4 (1), p.23-23, Article 23

2010

Volltextzugriff (PDF)

Pendent polyimides using mellitic acid dianhydride. III. The effect of pendent group functionality on polymer properties

Journal of applied polymer science, 2009-07, Vol.113 (2), p.1198-1206

2009

Volltextzugriff (PDF)

Abstract 3056: Growth differentiation factor 15 (GDF-15) inhibition attenuates platinum-based chemotherapy-induced emesis, anorexia and weight loss and increases survival

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.3056-3056

2020

Volltextzugriff (PDF)

Pharmacokinetics and Integrated PK/PD Modeling of a Novel Long Acting FGF21 Clinical Candidate PF-05231023 in Diet-Induced Obese and Leptin-Deficient Obese Mice

PloS one, 2015-03, Vol.10 (3)

2015

Volltextzugriff (PDF)

Comprehensive mechanism-based antibody pharmacokinetic modeling

2011 Annual International Conference of the IEEE Engineering in Medicine and Biology Society, 2011, Vol.2011, p.4318-4323

2011

Volltextzugriff (PDF)

Modeling Efficacy and Safety of Engineered Biologics

Drug Efficacy, Safety, and Biologics Discovery, 2008, p.301-326

2008

Volltextzugriff (PDF)

Analysis of Mechanistic Pathway Models in Drug Discovery : p38 Pathway : Integration of biological design principles from molecules to cells

Biotechnology progress, 2008, Vol.24 (1), p.96-109

2008

Volltextzugriff (PDF)

Drug Efficacy, Safety, and Biologics Discovery: Emerging Technologies and Tools

1. Aufl., 2009

Volltextzugriff (PDF)

1 – 25 von 30

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(25)
Mit Volltextzugriff
(29)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(20)
Life Sciences & Biomedicine
(11)
Animals
(8)
Humans
(7)
Multidisciplinary Sciences
(6)
Pharmacokinetics
(6)
Science & Technology - Other Topics
(6)
Body Weight
(5)
Male
(5)
Models, Biological
(5)
Pharmacology
(5)
Antibodies, Monoclonal, Humanized - Pharmacology
(3)
Antibodies, Monoclonal, Humanized - Therapeutic Use
(3)
Body Weight Loss
(3)
Drugs
(3)
Female
(3)
Fibroblast Growth Factors
(3)
Fibroblast Growth Factors - Therapeutic Use
(3)
Glucose
(3)
Liver
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects

Cellular Imaging Predictions of Clinical Drug-Induced Liver Injury

Pharmacokinetics (PK), pharmacodynamics (PD) and integrated PK/PD modeling of a novel long acting FGF21 clinical candidate PF-05231023 in diet-induced obese and leptin-deficient obese mice

Fc-GDF15 glyco-engineering and receptor binding affinity optimization for body weight regulation

Stochastic gene expression out-of-steady-state in the cyanobacterial circadian clock

Examination of the Human Cytochrome P4503A4 Induction Potential of PF-06282999, an Irreversible Myeloperoxidase Inactivator: Integration of Preclinical, In Silico, and Biomarker Methodologies in the Prediction of the Clinical Outcome

Probing Polymerization Forces by Using Actin-Propelled Lipid Vesicles

Assessing the Feasibility of Neutralizing Osteopontin with Various Therapeutic Antibody Modalities

A Mechanistic Site-Of-Action Model: A Tool for Informing Right Target, Right Compound, And Right Dose for Therapeutic Antagonistic Antibody Programs

Once‐weekly administration of a long‐acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with hypertriglyceridaemia and in non‐human primates

Social context of shell acquisition in Coenobita clypeatus hermit crabs

Small Molecule Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Hit to Lead Optimization of Systemic Agents

Liver‐Targeted Small‐Molecule Inhibitors of Proprotein Convertase Subtilisin/Kexin Type 9 Synthesis

Physiologically relevant binding affinity quantification of monoclonal antibody PF‐00547659 to mucosal addressin cell adhesion molecule for in vitro in vivo correlation

Glyco-engineered Long Acting FGF21 Variant with Optimal Pharmaceutical and Pharmacokinetic Properties to Enable Weekly to Twice Monthly Subcutaneous Dosing

Analysis of Mechanistic Pathway Models in Drug Discovery: p38 Pathway

Two additive mechanisms impair the differentiation of 'substrate-selective' p38 inhibitors from classical p38 inhibitors in vitro

Liver‐Targeted Small‐Molecule Inhibitors of Proprotein Convertase Subtilisin/Kexin Type 9 Synthesis

Pendent polyimides using mellitic acid dianhydride. III. The effect of pendent group functionality on polymer properties

Abstract 3056: Growth differentiation factor 15 (GDF-15) inhibition attenuates platinum-based chemotherapy-induced emesis, anorexia and weight loss and increases survival

Pharmacokinetics and Integrated PK/PD Modeling of a Novel Long Acting FGF21 Clinical Candidate PF-05231023 in Diet-Induced Obese and Leptin-Deficient Obese Mice

Comprehensive mechanism-based antibody pharmacokinetic modeling

Modeling Efficacy and Safety of Engineered Biologics

Analysis of Mechanistic Pathway Models in Drug Discovery : p38 Pathway : Integration of biological design principles from molecules to cells

Drug Efficacy, Safety, and Biologics Discovery: Emerging Technologies and Tools

Suchergebnisse filtern